Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Participants With Systemic Lupus Erythematosus (Japan)
jRCT2080223304Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Baricitinib with Placebo (2 arms).
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2080223304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223304.